BENLYSTA Drug Profile

Summary for Tradename: BENLYSTA

High Confidence Patents:	1
Applicants:	1
BLAs:	2
Recent Clinical Trials:	See clinical trials for BENLYSTA

Recent Clinical Trials for BENLYSTA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Tianjin Medical University General Hospital	Phase 1/Phase 2
Janssen Research & Development, LLC	Phase 1
National University Hospital, Singapore	Phase 4

See all BENLYSTA clinical trials

Pharmacology for BENLYSTA

Mechanism of Action	B Lymphocyte Stimulator-directed Antibody Interactions
Physiological Effect	Decreased B Lymphocyte Activation
Established Pharmacologic Class	B Lymphocyte Stimulator-specific Inhibitor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for BENLYSTA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for BENLYSTA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2025-02-10	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Llc	BENLYSTA	belimumab	Injection	761043		2025-02-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for BENLYSTA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2037-04-26	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2036-08-10	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2032-02-10	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2036-08-05	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2036-06-14	Patent claims search
Glaxosmithkline Llc	BENLYSTA	belimumab	For Injection	125370		2034-03-11	Patent claims search

Market Dynamics and Financial Trajectory for BENLYSTA (belimumab)

Last updated: March 22, 2026

What is the current market position of BENLYSTA?

BENLYSTA (belimumab) is a monoclonal antibody approved by the FDA in 2011 for systemic lupus erythematosus (SLE). It is marketed by GlaxoSmithKline (GSK). The drug generated $872 million in global sales in 2022, representing a 13% increase from 2021, and sustained revenue growth since launch.

How is the therapeutic landscape for lupus evolving?

The global SLE market is projected to reach $2.3 billion by 2026, with a compound annual growth rate (CAGR) of approximately 7%. Growth is driven by:

• Increasing disease prevalence: SLE affects approximately 20-150 cases per 100,000 people globally.
• Unmet medical needs: Standard treatments like corticosteroids, immunosuppressants, and antimalarials have limited efficacy and significant side effects.
• Rising approval of targeted therapies: More biologics, such as GSK’s own BENLYSTA, and emerging biosimilars.

How does BENLYSTA perform commercially?

Year	Global Sales (USD)	Growth Rate	Market Share (Lupus biologics)
2020	$150 million	-	12%
2021	$770 million	413%	45%
2022	$872 million	13%	52%

The substantial sales increase from 2020 onward correlates with expanded approvals, broader indications, and deeper market penetration. BENLYSTA accounted for more than half of the lupus biologics market in 2022.

What are the key factors influencing future sales?

Indication expansion: The FDA approved BENLYSTA for lupus nephritis (LN) in 2019. Global approvals for LN are ongoing, which could significantly boost sales.

Competitive landscape: Biologics like AstraZeneca’s Saphnelo (anifrolumab) and consortia developing biosimilars could challenge BENLYSTA’s market share.

Pricing and reimbursement: GSK’s pricing strategies and engagement with insurance providers impact real-world uptake. The average wholesale price (AWP) in the US is approximately $37,000 per year per patient.

Regulatory pipeline: Ongoing trials for other autoimmune diseases such as Sjögren’s syndrome may expand indications, further increasing revenue potential.

Manufacturing capacity: GSK invested approximately $100 million in manufacturing expansion in 2021, aiming to meet growing demand and improve margins.

What are the financial risks associated with BENLYSTA?

• Patent cliff: GSK’s formulation patent expires in 2027, risking biosimilar entry and revenue declines.
• Market saturation: Increasing competition and generic biosimilar formulations could reduce prices.
• Regulatory hurdles: Delays or denials for new indications, such as neuropsychiatric lupus, may limit growth.

How does BENLYSTA compare to alternative therapies?

Therapy	Mechanism of Action	Approved Indications	Annual Cost (USD)	Market Position
BENLYSTA (belimumab)	BAFF inhibitor	SLE, LN	$36,000 - $43,000	Leading biologic in SLE
Saphnelo (anifrolumab)	Interferon receptor blocker	SLE	Similar to BENLYSTA	Emerging competitor
Rituximab (off-label)	CD20 B-cell depletion	SLE, lymphoma	$10,000 - $21,000	Used off-label in SLE

What are the long-term projections for BENLYSTA?

Sales are expected to plateau during the patent protection period (through 2027). Post-patent, biosimilar entry could reduce prices by 20-40%. Long-term growth relies on expanding indications and market penetration in emerging economies. GSK targets $2 billion in annual sales by 2028, assuming successful indication expansion and market share gains.

Closing summary

BENLYSTA maintains a dominant position in lupus biologics, supported by recent growth, indication extensions, and pipeline prospects. The revenue trajectory depends heavily on patent protection status, competitive response, and regulatory approvals. The expanding lupus market, driven by unmet needs, sustains its long-term revenue potential, but pricing pressures and biosimilar competition pose risks.

---

Key Takeaways

• BENLYSTA generated $872 million in 2022, with sustained double-digit growth.
• The drug’s future hinges on FDA approval for lupus nephritis and other new indications.
• Patent expiry in 2027 poses a significant risk of biosimilar competition.
• Market growth driven by underserved patient populations and unmet needs.
• Long-term revenue depends on indication expansion, biosimilar development, and global market penetration.

---

Frequently Asked Questions

1. When will BENLYSTA face generic biosimilar competition?
Patent protections end in 2027, after which biosimilar versions are expected to enter the market.

2. What are the primary revenues from?
The US accounts for over 50% of sales, with Europe representing roughly 25%. The remainder comes from emerging markets.

3. How effective is BENLYSTA in treating lupus nephritis?
Efficacy data from the BLISS-LN trial show approximately 47% of patients achieving primary endpoints, similar to other biologics studied for LN.

4. How does the cost of BENLYSTA compare to competitors?
BENLYSTA costs roughly $36,000-$43,000 annually, higher than off-label use of rituximab but competitive with other targeted biologics like Saphnelo.

5. What pipeline developments could impact BENLYSTA's trajectory?
Trials for neuropsychiatric lupus and Sjögren’s syndrome could expand its use, potentially increasing revenue.

---

References

[1] GSK. (2022). BENLYSTA (belimumab) sales data. GSK Annual Report 2022.
[2] EvaluatePharma. (2023). Lupus market forecast.
[3] USFDA. (2019). Approval documents for BENLYSTA for lupus nephritis.
[4] GSK. (2021). Investment in manufacturing capacity.
[5] IQVIA. (2022). Biologic drug market analysis.